Rexulti shortage: What providers and prescribers need to know in 2026

Your patients taking Rexulti (brexpiprazole) may be telling you they can't get their prescriptions filled. While Rexulti is not on the FDA's official drug shortage list as of 2026, real-world availability barriers are causing meaningful treatment gaps for a significant number of patients.

This post is a clinical and practical overview of the Rexulti availability landscape in 2026 — what's driving patient access issues, and how prescribers can proactively support continuity of care.

The current availability landscape

Rexulti scores a 62 out of 100 on Medfinder's findability scale. It is generally available at major chain pharmacies but inconsistently stocked at smaller and independent pharmacies. The core supply issue is not manufacturing — Otsuka continues to produce sufficient volume — but distribution and pharmacy inventory management.

As a brand-name-only specialty medication with a WAC of approximately $1,515/month (as of January 2025), pharmacies order Rexulti on a per-patient just-in-time basis. Disruptions in regional wholesale supply chains — not uncommon with expensive specialty drugs — lead to multi-day delays that patients experience as a shortage.

Generic brexpiprazole: What prescribers should know

The FDA approved a generic brexpiprazole from Alembic Pharmaceuticals in January 2025. However, Rexulti is protected by a complex patent estate — including a key formulation patent with an expiration of October 2032 and potential litigation extending market exclusivity until April 2033.

Prescribers should not counsel patients to expect generic brexpiprazole availability in 2026. While tentative approvals have been granted to multiple manufacturers (including Alembic and Sandoz), the drug cannot be commercially marketed until patent and exclusivity issues are resolved.

Insurance access barriers: PA and step therapy

Coverage for Rexulti is broad but often restricted. According to GoodRx data, approximately 83% of commercial insurance plans cover Rexulti, but many require prior authorization and/or step therapy. Medicaid covers Rexulti for nearly all enrollees, but 3 in 4 require prior authorization and close to 2 in 3 must complete step therapy first.

For prescribers, this means that a significant portion of new Rexulti prescriptions will require proactive authorization work. Delays in PA submission — or initial rejections that aren't appealed — result in patients being unable to fill their prescriptions for days or weeks.

• Commercial plans: Document failure of or contraindication to at least one adequate antidepressant trial (for MDD adjunctive use). For schizophrenia, document previous treatment history and clinical rationale for brexpiprazole.
• Medicaid: Most state Medicaid programs require step therapy through at least two generic alternatives. Prepare to document the clinical rationale for advancing to Rexulti specifically.
• Medicare Part D: Rexulti is covered by most Part D plans but often placed on specialty tiers. The 2026 annual out-of-pocket cap of $2,100 improves patient affordability, but prior authorization remains a common requirement.

Clinical implications of treatment gaps

Rexulti is not a drug that can be abruptly stopped without risk. For patients with schizophrenia, even brief treatment gaps can precipitate symptom exacerbation or relapse. For patients using Rexulti as adjunctive therapy for MDD, unexpected discontinuation may trigger a depressive episode.

When patients report that they cannot fill their prescription, treat it as a clinical priority — not an administrative delay. Consider providing bridge supplies from office samples when available, and have your staff proactively follow up on any stalled PA requests.

Therapeutic alternatives when access fails

If access barriers cannot be resolved promptly, the closest pharmacological alternative to brexpiprazole is aripiprazole (Abilify). Both are dopamine D2 partial agonists with similar efficacy profiles for MDD augmentation and schizophrenia. Generic aripiprazole is widely available and costs roughly $5–$88 per month. Note that aripiprazole carries a higher risk of akathisia due to greater D2 intrinsic activity. See our full guide to Rexulti alternatives for clinical comparisons across indications.

Resources for your patients

Equipping your patients with the right tools is as important as the prescription itself. Refer them to Medfinder's provider resources to locate pharmacy stock in real time. Otsuka Patient Support (1-833-468-7852) can help patients navigate both access and cost issues. For commercially insured patients, the Rexulti Savings Card can reduce out-of-pocket costs to as little as $0. For uninsured patients, the Otsuka Patient Assistance Foundation (OPAF) provides the medication at no charge to eligible patients.